Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma—Polish Lymphoma Research Group real-life analysis

A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial

“…An analysis of the Polish group evaluating efficacy in a more homogenous group of patients confirmed the promising efficacy, but follow-up was short in both trials, which does not allow comparing long-term results. 29,30 The Pix306 trial tested rituximab-pixantrone versus rituximab-pixantrone, Selective: only events grade 3/4 (>5%) or with a frequency >10% or events of special interest are selected. a Lymphopenia was an expected adverse reaction in the treatment with obinutuzumab and pixantrone and was therefore not documented as an adverse event.…”

“…In this mixed‐bag trial, an ORR of 53% was observed. An analysis of the Polish group evaluating efficacy in a more homogenous group of patients confirmed the promising efficacy, but follow‐up was short in both trials, which does not allow comparing long‐term results 29,30 . The Pix306 trial tested rituximab–pixantrone versus rituximab–pixantrone, without demonstrating superiority of R‐Pix over R‐Gem.…”

Current status and achievements of Polish haemato-oncology

“…Pre-existing diabetes was identified as an independent risk factor of adverse prognosis [45]. In a multicentre approach, PLRG investigated the efficacy of the PREBEN regimen (pixantrone, rituximab, etoposide, and bendamustine) in relapsing refractory cases [46].…”

Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma

“…Quite important, however, was the observation that response rates were even higher in patients chemosensitive to their prior regimen (ORR 87.5%; including 50% CR). 53 Different in terms of efficacy were, however, the outcomes of another real-world study by Novakovic et al, reporting treatment results of twelve consecutive patients treated with pixantrone monotherapy (2 patients) or PREBEN/PEBEN (8/2 patients, respectively). 17 The prognostic features of these patients were far worse compared to the Polish analysis 53 and the preliminary study of d'Amore, 48 with 100% of patients having been refractory to last treatment and a high proportion of primary refractory disease, as well as insensitivity to primary anthracycline treatment by PIX301 criteria.…”

“…It has been proven efficacious while exhibiting acceptable toxicity in monotherapy, 11,[40][41][42] as well as in combinations, for R/R aggressive lymphomas. [46][47][48][49][52][53][54] Certain studies, 15,17,48 however, have stated its lesser activity in refractory patients compared to relapsed ones and most of real-world analyses have shown inferior results compared to trial results, ostensibly at least partly on account of inclusion of patients with poor risk characteristics. [15][16][17] Nevertheless, a good number of studies evaluated only clinical features of patients, with very few studies addressing the relation of histological characteristics of lymphomas to clinical outcome.…”